Addex Therapeutics Terminates Epilepsy Program, Stock Surges
Monday, 22 July 2024, 15:09
Addex Therapeutics' Epilepsy Program Ends
End of April marked a significant moment for Addex Therapeutics, as it announced that the Phase II study for its product candidate ADX71149 (JNJ-40411813) did not meet its set goals. This outcome prompted the decision to halt the epilepsy program, raising questions about the company's future strategies.
Market Reaction to the News
Despite the setback in its epilepsy efforts, Addex Therapeutics stock saw an increase, possibly influenced by investor optimism and market dynamics.
Implications for the Future
- Shift in focus to other product candidates
- Ongoing assessment of market opportunities
- Potential for collaboration with Janssen Pharmaceutica in the future
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.